Literature DB >> 18343551

Memantine decreases hippocampal glutamate levels: a magnetic resonance spectroscopy study.

Lidia Glodzik1, Kevin G King, Oded Gonen, Songtao Liu, Susan De Santi, Mony J de Leon.   

Abstract

Glutamate (Glu) is associated with excitotoxic cell damage. Memantine modulates the glutamate induced excitotoxicity in Alzheimer's disease (AD). No information is available as to the influence of memantine on in vivo brain glutamate levels. Hippocampal Glu levels were measured in cognitively impaired and normal individuals (n=10) before and after 6 months of memantine treatment, using three dimensional high spatial resolution (0.5 cm(3) voxels) proton magnetic resonance spectroscopy at 3 T. These measurements were also repeated in a non-treated cognitively normal group (n=6). Treatment with memantine decreased Glu/Cr (creatine) ratio in the left hippocampal region. Memantine reduced hippocampal glutamate levels, which may be consistent with its anti-excitotoxic property.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18343551      PMCID： PMC2789554          DOI： 10.1016/j.pnpbp.2008.01.016

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN： 0278-5846            Impact factor:   5.067


  34 in total

1.  Effect of windowing and zero-filled reconstruction of MRI data on spatial resolution and acquisition strategy.

Authors:  M A Bernstein; S B Fain; S J Riederer
Journal:  J Magn Reson Imaging       Date:  2001-09       Impact factor: 4.813

2.  Decreased glutamate + glutamine in Alzheimer's disease detected in vivo with (1)H-MRS at 0.5 T.

Authors:  P G Antuono; J L Jones; Y Wang; S J Li
Journal:  Neurology       Date:  2001-03-27       Impact factor: 9.910

3.  Selective Fourier transform localization.

Authors:  H R Brooker; T H Mareci; J T Mao
Journal:  Magn Reson Med       Date:  1987-11       Impact factor: 4.668

Review 4.  Spatial localization in NMR spectroscopy in vivo.

Authors:  P A Bottomley
Journal:  Ann N Y Acad Sci       Date:  1987       Impact factor: 5.691

5.  Hippocampal structures: anteroposterior N-acetylaspartate differences in patients with epilepsy and control subjects as shown with proton MR spectroscopic imaging.

Authors:  P Vermathen; K D Laxer; G B Matson; M W Weiner
Journal:  Radiology       Date:  2000-02       Impact factor: 11.105

6.  Proton MR spectroscopic study at 3 Tesla on glutamate/glutamine in Alzheimer's disease.

Authors:  Noriaki Hattori; Kazuo Abe; Saburo Sakoda; Tohru Sawada
Journal:  Neuroreport       Date:  2002-01-21       Impact factor: 1.837

7.  Regional N-acetylaspartate reduction in the hippocampus detected with fast proton magnetic resonance spectroscopic imaging in patients with Alzheimer disease.

Authors:  Wolfgang Block; Frank Jessen; Frank Träber; Sebastian Flacke; Christoph Manka; Rolf Lamerichs; Ewald Keller; Reinhard Heun; Hans Schild
Journal:  Arch Neurol       Date:  2002-05

8.  [3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients.

Authors:  J Kornhuber; F Mack-Burkhardt; P Riederer; G F Hebenstreit; G P Reynolds; H B Andrews; H Beckmann
Journal:  J Neural Transm       Date:  1989       Impact factor: 3.575

9.  Regulation of phosphate-activated glutaminase (PAG) by glutamate analogues.

Authors:  R Dawson; D R Wallace
Journal:  Neurochem Res       Date:  1993-02       Impact factor: 3.996

10.  Constitutive endocytosis and recycling of the neuronal glutamate transporter, excitatory amino acid carrier 1.

Authors:  Marco I González; Bala T S Susarla; Keith M Fournier; Amanda L Sheldon; Michael B Robinson
Journal:  J Neurochem       Date:  2007-09-14       Impact factor: 5.372
View more
  7 in total

1.  Proton MR spectroscopy-detectable major neurotransmitters of the brain: biology and possible clinical applications.

Authors:  N Agarwal; P F Renshaw
Journal:  AJNR Am J Neuroradiol       Date:  2011-12-29       Impact factor: 3.825

Review 2.  Memantine: a review of its use in moderate to severe Alzheimer's disease.

Authors:  Kate McKeage
Journal:  CNS Drugs       Date:  2009-10       Impact factor: 5.749

3.  Memantine for dementia.

Authors:  Rupert McShane; Maggie J Westby; Emmert Roberts; Neda Minakaran; Lon Schneider; Lucy E Farrimond; Nicola Maayan; Jennifer Ware; Jean Debarros
Journal:  Cochrane Database Syst Rev       Date:  2019-03-20

4.  Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS).

Authors:  Giles My Tan; Felix Beacher; Eileen Daly; Jamie Horder; Verinder Prasher; Maria-Luisa Hanney; Robin Morris; Simon Lovestone; Kieran C Murphy; Andrew Simmons; Declan Gm Murphy
Journal:  J Neurodev Disord       Date:  2014-11-27       Impact factor: 4.025

Review 5.  Advances in high-field magnetic resonance spectroscopy in Alzheimer's disease.

Authors:  Ningnannan Zhang; Xiaowei Song; Robert Bartha; Steven Beyea; Ryan D'Arcy; Yunting Zhang; Kenneth Rockwood
Journal:  Curr Alzheimer Res       Date:  2014-05       Impact factor: 3.498

6.  Evaluation of the efficacy of memantine in the treatment of fibromyalgia: study protocol for a doubled-blind randomized controlled trial with six-month follow-up.

Authors:  Bárbara Olivan-Blázquez; Marta Puebla; Bárbara Masluk; Mari-Cruz Pérez-Yus; Raquel Arcega; Eva Andrés; Yolanda López-del-Hoyo; Rosa Magallon; Miquel Roca; Javier Garcia-Campayo
Journal:  Trials       Date:  2013-01-03       Impact factor: 2.279

Review 7.  Memantine and Kynurenic Acid: Current Neuropharmacological Aspects.

Authors:  Zsófia Majláth; Nóra Török; József Toldi; László Vécsei
Journal:  Curr Neuropharmacol       Date:  2016       Impact factor: 7.363
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.